BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Humphrey PA. Histopathology of Prostate Cancer. Cold Spring Harb Perspect Med 2017;7:a030411. [PMID: 28389514 DOI: 10.1101/cshperspect.a030411] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang S, Wei W, Ma N, Qu Y, Liu Q. Molecular mechanisms of ferroptosis and its role in prostate cancer therapy. Crit Rev Oncol Hematol 2022;176:103732. [PMID: 35697233 DOI: 10.1016/j.critrevonc.2022.103732] [Reference Citation Analysis]
2 He J, Zhou Y, Arredondo Carrera HM, Sprules A, Neagu R, Zarkesh SA, Eaton C, Luo J, Gartland A, Wang N. Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target. Cells 2020;9:E2511. [PMID: 33233569 DOI: 10.3390/cells9112511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Van Booven DJ, Kuchakulla M, Pai R, Frech FS, Ramasahayam R, Reddy P, Parmar M, Ramasamy R, Arora H. A Systematic Review of Artificial Intelligence in Prostate Cancer. Res Rep Urol 2021;13:31-9. [PMID: 33520879 DOI: 10.2147/RRU.S268596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Li H, Lee CH, Chia D, Lin Z, Huang W, Tan CH. Machine Learning in Prostate MRI for Prostate Cancer: Current Status and Future Opportunities. Diagnostics (Basel) 2022;12:289. [PMID: 35204380 DOI: 10.3390/diagnostics12020289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 PĂnuŞ A, Simionescu CE, DrĂgoescu PO, Tomescu P, Stepan AE. Analysis of Prostate Adenocarcinoma Histopathological Types in Relation to Tumor Grade. Curr Health Sci J 2020;46:405-11. [PMID: 33717516 DOI: 10.12865/CHSJ.46.04.12] [Reference Citation Analysis]
6 Aggarwal S, Mitra S, Dewan A, Durga G. Carcinosarcoma prostate with osteosarcomatous differentiation: a rare de novo presentation. BMJ Case Rep 2019;12:e230116. [PMID: 31196973 DOI: 10.1136/bcr-2019-230116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Sood RR, Shao W, Kunder C, Teslovich NC, Wang JB, Soerensen SJC, Madhuripan N, Jawahar A, Brooks JD, Ghanouni P, Fan RE, Sonn GA, Rusu M. 3D Registration of pre-surgical prostate MRI and histopathology images via super-resolution volume reconstruction. Med Image Anal 2021;69:101957. [PMID: 33550008 DOI: 10.1016/j.media.2021.101957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Inamura K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget 2018;9:14723-37. [PMID: 29581876 DOI: 10.18632/oncotarget.24515] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kader A, Brangsch J, Kaufmann JO, Zhao J, Mangarova DB, Moeckel J, Adams LC, Sack I, Taupitz M, Hamm B, Makowski MR. Molecular MR Imaging of Prostate Cancer. Biomedicines 2020;9:1. [PMID: 33375045 DOI: 10.3390/biomedicines9010001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Deng Y, Bi R, Zhu Z, Li S, Xu B, Rather WA, Wang C. A Surveillance, Epidemiology and End Results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma. Oncol Lett 2019;18:1057-70. [PMID: 31423166 DOI: 10.3892/ol.2019.10461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Dills A, Obi O, Bustos K, Jiang J, Gupta S. Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease. J Investig Med High Impact Case Rep 2021;9:2324709621990769. [PMID: 33596692 DOI: 10.1177/2324709621990769] [Reference Citation Analysis]
12 Mei JJ, Zhao YX, Jiang Y, Wang J, Yu JS. Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment. Cancer Manag Res 2020;12:4959-68. [PMID: 32636672 DOI: 10.2147/CMAR.S250907] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, Haberkorn U, Giesel F, Rahbar K. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med 2021. [PMID: 34854061 DOI: 10.1007/s12149-021-01702-8] [Reference Citation Analysis]
14 Jin C, Zhao W, Zhang Z, Liu W. CircLMTK2 acts as a tumor suppressor in prostate cancer via regulating the expression of microRNA-183. Life Sci 2020;241:117097. [PMID: 31760099 DOI: 10.1016/j.lfs.2019.117097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Murray TBJ. The Pathogenesis of Prostate Cancer. In: Bott SR, Lim Ng K, editors. Prostate Cancer. Exon Publications; 2021. pp. 29-42. [DOI: 10.36255/exonpublications.prostatecancer.pathogenesis.2021] [Reference Citation Analysis]
16 Campaña J, Bernal P. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavorable intermediate and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2021;48:2670-1. [PMID: 33944959 DOI: 10.1007/s00259-021-05369-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shao Y, Nir G, Fazli L, Goldenberg L, Gleave M, Black P, Wang J, Salcudean S. Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. Comput Biol Med 2020;127:104053. [PMID: 33126125 DOI: 10.1016/j.compbiomed.2020.104053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chi Z, Chen L, Huang J, Jiang N, Zheng Q, Huang N, Yang W. A novel combination of percutaneous stenting with iodine-125 seed implantation and chemotherapy for the treatment of pancreatic head cancer with obstructive jaundice. Brachytherapy 2021;20:218-25. [PMID: 33158777 DOI: 10.1016/j.brachy.2020.09.009] [Reference Citation Analysis]
19 Sun X, Huang Q, Peng F, Wang J, Zhao W, Guo G. Expression and Clinical Significance of HKII and HIF-1α in Grade Groups of Prostate Cancer. Front Genet 2021;12:680928. [PMID: 34220956 DOI: 10.3389/fgene.2021.680928] [Reference Citation Analysis]
20 Destouni M, Lazaris AC, Tzelepi V. Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance. Cancers 2022;14:3041. [DOI: 10.3390/cancers14133041] [Reference Citation Analysis]
21 Liyanage T, Alharbi B, Quan L, Esquela-Kerscher A, Slaughter G. Plasmonic-Based Biosensor for the Early Diagnosis of Prostate Cancer. ACS Omega 2022;7:2411-8. [PMID: 35071928 DOI: 10.1021/acsomega.1c06479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Carr AV, Frey BL, Scalf M, Cesnik AJ, Rolfs Z, Pike KA, Yang B, Keller MP, Jarrard DF, Shortreed MR, Smith LM. MetaNetwork Enhances Biological Insights from Quantitative Proteomics Differences by Combining Clustering and Enrichment Analyses. J Proteome Res . [DOI: 10.1021/acs.jproteome.1c00756] [Reference Citation Analysis]
23 Nguyen JK, Chen YY, Magi-Galluzzi C, McKenney JK. Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features. Am J Surg Pathol 2020;44:1635-42. [PMID: 32991340 DOI: 10.1097/PAS.0000000000001550] [Reference Citation Analysis]
24 Grypari IM, Logotheti S, Lazaris AC, Kallidonis P, Fokaefs E, Melachrinou M, Zolota V, Tzelepi V. Isolated Intraductal Carcinoma of the Prostate in Prostatectomy Specimens: Report of 2 Cases and Review of the Literature. Int J Surg Pathol 2020;28:918-24. [PMID: 32456482 DOI: 10.1177/1066896920920357] [Reference Citation Analysis]
25 Saranyutanon S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP. Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research. Cancers (Basel) 2020;12:E2651. [PMID: 32957478 DOI: 10.3390/cancers12092651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Manafi-Farid R, Ranjbar S, Jamshidi Araghi Z, Pilz J, Schweighofer-Zwink G, Pirich C, Beheshti M. Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. Cancers (Basel) 2021;13:5360. [PMID: 34771523 DOI: 10.3390/cancers13215360] [Reference Citation Analysis]
27 Silk N, Reich J, Sinha R, Chawla S, Geary K, Zhang D. The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment. J Xenobiot 2021;11:16-32. [PMID: 33535458 DOI: 10.3390/jox11010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Santos SAA, Camargo ACL, Constantino FB, Colombelli KT, Portela LMF, Fioretto MN, Vieira JCS, Padilha PM, de Oliveira MB, Felisbino SL, Carvalho RF, Justulin LA. Identification of potential molecular pathways involved in prostate carcinogenesis in offspring exposed to maternal malnutrition. Aging (Albany NY) 2020;12:19954-78. [PMID: 33049715 DOI: 10.18632/aging.104093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampouna S. The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. Cancers (Basel) 2020;12:E1887. [PMID: 32668821 DOI: 10.3390/cancers12071887] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
30 Li W, Shen MM. Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models. Semin Cancer Biol 2021:S1044-579X(21)00186-3. [PMID: 34147640 DOI: 10.1016/j.semcancer.2021.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 García Trevijano Cabetas M, Escario-Gómez M, González-Del Valle L, Sobrino Jiménez C, Bilbao Gomez-Martino C, Romero-Garrido JA, Benedi-González J, Espinosa Arranz E, Díaz Almirón M, Herrero Ambrosio A. Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most? Eur J Hosp Pharm 2021:ejhpharm-2021-002798. [PMID: 34620687 DOI: 10.1136/ejhpharm-2021-002798] [Reference Citation Analysis]
32 Yu Y, Lajkosz K, Finelli A, Fleshner N, van der Kwast TH, Downes MR. Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification. Mod Pathol. [DOI: 10.1038/s41379-022-01111-w] [Reference Citation Analysis]
33 Yang M, Zhang X, Guo L, Liu X, Wu J, Zhu H. Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment. Biomed Res Int 2021;2021:6230826. [PMID: 33506020 DOI: 10.1155/2021/6230826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ayyad SM, Shehata M, Shalaby A, Abou El-Ghar M, Ghazal M, El-Melegy M, Abdel-Hamid NB, Labib LM, Ali HA, El-Baz A. Role of AI and Histopathological Images in Detecting Prostate Cancer: A Survey. Sensors (Basel) 2021;21:2586. [PMID: 33917035 DOI: 10.3390/s21082586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]